{"url_path":"/sec/tvtx/8-k/2026-06-16/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000048-index.html","accession_number":"0001438533-26-000048","cik":"0001438533","ticker":"TVTX","issuer_name":"Travere Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000048-index.html","primary_entity_key":"0001438533","primary_entity_name":"Travere Therapeutics, Inc."},"word_count":446,"has_tables":true,"body_markdown":"Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the “Retirement Date”), the 10 year anniversary of his employment with the Company.\n\nIt is expected that Dr. Rote will continue to serve in his current position through the Retirement Date and will assist in the transition of his responsibilities. The responsibilities currently overseen by Dr. Rote are expected to be assumed by Jula Inrig, M.D., the Company's Chief Medical Officer. Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.\n\nThe Company expects to enter into a consulting arrangement with Dr. Rote to enable continued access to Dr. Rote following his retirement.\n\nForward-Looking Statements\n\nThis report contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements and expectations regarding the planned retirement of Dr. Rote and the planned changes to Dr. Inrig’s title and responsibilities, and the expected timing thereof; and the expectation to enter into a consulting agreement with Dr. Rote. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to human capital and the Company’s business needs and resources. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n    TRAVERE THERAPEUTICS, INC.\n\n    \n\nDated: June 16, 2026   By:/s/ Eric Dube\n\n      Name:Eric Dube\n\nTitle:Chief Executive Officer"}